126 related articles for article (PubMed ID: 28258356)
1. The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.
Oortgiesen BE; van Roon EN; Joosten P; Kibbelaar RE; Storm H; Hovenga S; van Rees B; Woolthuis G; Veeger N; de Waal EG; Hoogendoorn M
Eur J Clin Pharmacol; 2017 Jun; 73(6):771-778. PubMed ID: 28258356
[TBL] [Abstract][Full Text] [Related]
2. Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.
de Vries JC; Oortgiesen B; Hemmelder MH; van Roon E; Kibbelaar RE; Veeger N; Hoogendoorn M
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28278719
[TBL] [Abstract][Full Text] [Related]
3. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.
Trakada G; Kastritis E; Gavriatopoulou M; Velentza L; Fotiou D; Ziogas DC; Panagiotidis I; Eleutherakis-Papaiakovou E; Roussou M; Migkou M; Kanellias N; Ntanasis-Stathopoulos I; Kallianos A; Terpos E; Dimopoulos MA
Ann Hematol; 2019 Jun; 98(6):1427-1434. PubMed ID: 30834954
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.
Jung SH; Cho MS; Kim HK; Kim SJ; Kim K; Cheong JW; Kim SJ; Kim JS; Ahn JS; Kim YK; Yang DH; Kim HJ; Lee JJ;
BMC Cancer; 2016 Aug; 16():613. PubMed ID: 27501959
[TBL] [Abstract][Full Text] [Related]
7. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
Farag S; van Coevorden F; Sneekes E; Grunhagen DJ; Reyners AKL; Boonstra PA; van der Graaf WT; Gelderblom HJ; Steeghs N
Eur J Cancer; 2017 Nov; 86():318-325. PubMed ID: 29073582
[TBL] [Abstract][Full Text] [Related]
8. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
[TBL] [Abstract][Full Text] [Related]
10. Novel agents have a significant impact on survival of patients with multiple myeloma.
Lamm W; Eder S; Bojic M; Zielinski CC; Drach J
Wien Klin Wochenschr; 2015 Feb; 127(3-4):92-7. PubMed ID: 25609569
[TBL] [Abstract][Full Text] [Related]
11. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P; Hutchison CA; Basnayake K; Stringer S; Jesky M; Fifer L; Snell K; Pinney J; Drayson MT; Cook M; Cockwell P
Eur J Haematol; 2016 Jun; 96(6):610-7. PubMed ID: 26248588
[TBL] [Abstract][Full Text] [Related]
12. Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Thoennissen GB; Görlich D; Bacher U; Aufenberg T; Hüsken AC; Hansmeier AA; Evers G; Mikesch JH; Fritz F; Bokemeyer C; Müller-Tidow C; Stelljes M; Mesters RM; Krug U; Kropff MH; Thoennissen NH; Berdel WE
Acta Haematol; 2017; 137(3):163-172. PubMed ID: 28399522
[TBL] [Abstract][Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
14. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
Huang TC; Chen JH; Wu YY; Chang PY; Dai MS; Chao TY; Kao WY; Chen YC; Ho CL
Ann Hematol; 2015 Jan; 94(1):107-15. PubMed ID: 25047657
[TBL] [Abstract][Full Text] [Related]
15. Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
Offidani M; Corvatta L; Polloni C; Centurioni R; Visani G; Brunori M; Gentili S; Catarini M; Samori A; Blasi N; Alesiani F; Caraffa P; Burattini M; Galieni P; Fraticelli P; Ferranti M; Giuliodori L; Leoni P
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):423-32. PubMed ID: 22981966
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
[TBL] [Abstract][Full Text] [Related]
17. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
18. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation.
Hwa YL; Shi Q; Kumar SK; Lacy MQ; Gertz MA; Kapoor P; Buadi FK; Leung N; Dingli D; Go RS; Hayman SR; Gonsalves WI; Russell S; Lust JA; Lin Y; Rajkumar SV; Dispenzieri A
Am J Hematol; 2017 Jan; 92(1):50-55. PubMed ID: 27733010
[TBL] [Abstract][Full Text] [Related]
19. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.
Nasr SH; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Lacy M; Dispenzieri A; Rajkumar SV; Kyle RA; Leung N
Am J Kidney Dis; 2012 Jun; 59(6):786-94. PubMed ID: 22417785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
